Loading…
Management strategies in patients with statin-associated muscle symptoms: What is the best strategy?
Highlights • Statin-associated muscle symptoms (SAMS) are commonly encountered. • Strategies are rechallenge, switch, nondaily statin dosing, or nonstatins. • Tolerability of each of these strategies is over 60%; efficacy is variable. • Several limitations are still encountered in the management of...
Saved in:
Published in: | Journal of clinical lipidology 2016-09, Vol.10 (5), p.1067-1072 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c411t-4dcfb6bd9cba997180fee32372c96e321e03a34ec5afc197e2145a6b91a74b223 |
---|---|
cites | cdi_FETCH-LOGICAL-c411t-4dcfb6bd9cba997180fee32372c96e321e03a34ec5afc197e2145a6b91a74b223 |
container_end_page | 1072 |
container_issue | 5 |
container_start_page | 1067 |
container_title | Journal of clinical lipidology |
container_volume | 10 |
creator | Joy, Tisha R., MD, FRCPC, FACE Brennan, Emily T., MD, FRCPC |
description | Highlights • Statin-associated muscle symptoms (SAMS) are commonly encountered. • Strategies are rechallenge, switch, nondaily statin dosing, or nonstatins. • Tolerability of each of these strategies is over 60%; efficacy is variable. • Several limitations are still encountered in the management of patients with SAMS. • Ultimately, patient involvement determines which strategy is most acceptable. |
doi_str_mv | 10.1016/j.jacl.2016.06.008 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1824545984</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1933287416302276</els_id><sourcerecordid>1824545984</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-4dcfb6bd9cba997180fee32372c96e321e03a34ec5afc197e2145a6b91a74b223</originalsourceid><addsrcrecordid>eNp9UcuKFTEQDaI44-gPuJAs3fQ1r-4kIooMvmDEhYrLkE5Xz03bjzuptHL_3jR3nIULoSCnknMOlVOEPOVsxxlvXgy7wYdxJwresVLM3CPn3OimUtrY-wVbKSthtDojjxAHxupas_ohORO60UYJcU66z3721zDBnCnm5DNcR0AaZ3rwOZZbpL9j3pe30s6VR1xCLKyOTiuGESgep0NeJnxJf-x9phFp3gNtAe_8jm8ekwe9HxGe3J4X5Pv7d98uP1ZXXz58unx7VQXFea5UF_q2aTsbWm-t5ob1AFJILYJtCuDApJcKQu37wK0GwVXtm9Zyr1UrhLwgz0--h7TcrGUEN0UMMI5-hmVFx41QtaqtUYUqTtSQFsQEvTukOPl0dJy5LV03uC1dt6XrWClmiujZrf_aTtDdSf7GWQivTgQov_wVITkMJcQAXUwQsuuW-H__1__IwxjnGPz4E46Aw7KmueTnuEPhmPu67XdbL28kE2UI-Qf206HF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1824545984</pqid></control><display><type>article</type><title>Management strategies in patients with statin-associated muscle symptoms: What is the best strategy?</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Joy, Tisha R., MD, FRCPC, FACE ; Brennan, Emily T., MD, FRCPC</creator><creatorcontrib>Joy, Tisha R., MD, FRCPC, FACE ; Brennan, Emily T., MD, FRCPC</creatorcontrib><description>Highlights • Statin-associated muscle symptoms (SAMS) are commonly encountered. • Strategies are rechallenge, switch, nondaily statin dosing, or nonstatins. • Tolerability of each of these strategies is over 60%; efficacy is variable. • Several limitations are still encountered in the management of patients with SAMS. • Ultimately, patient involvement determines which strategy is most acceptable.</description><identifier>ISSN: 1933-2874</identifier><identifier>EISSN: 1876-4789</identifier><identifier>DOI: 10.1016/j.jacl.2016.06.008</identifier><identifier>PMID: 27678422</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Cardiovascular ; Dose-Response Relationship, Drug ; Drug Substitution - methods ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects ; Lipid Metabolism - drug effects ; Medication Therapy Management ; Muscular Diseases - etiology ; Muscular Diseases - prevention & control</subject><ispartof>Journal of clinical lipidology, 2016-09, Vol.10 (5), p.1067-1072</ispartof><rights>National Lipid Association</rights><rights>2016 National Lipid Association</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-4dcfb6bd9cba997180fee32372c96e321e03a34ec5afc197e2145a6b91a74b223</citedby><cites>FETCH-LOGICAL-c411t-4dcfb6bd9cba997180fee32372c96e321e03a34ec5afc197e2145a6b91a74b223</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27678422$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Joy, Tisha R., MD, FRCPC, FACE</creatorcontrib><creatorcontrib>Brennan, Emily T., MD, FRCPC</creatorcontrib><title>Management strategies in patients with statin-associated muscle symptoms: What is the best strategy?</title><title>Journal of clinical lipidology</title><addtitle>J Clin Lipidol</addtitle><description>Highlights • Statin-associated muscle symptoms (SAMS) are commonly encountered. • Strategies are rechallenge, switch, nondaily statin dosing, or nonstatins. • Tolerability of each of these strategies is over 60%; efficacy is variable. • Several limitations are still encountered in the management of patients with SAMS. • Ultimately, patient involvement determines which strategy is most acceptable.</description><subject>Cardiovascular</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Substitution - methods</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</subject><subject>Lipid Metabolism - drug effects</subject><subject>Medication Therapy Management</subject><subject>Muscular Diseases - etiology</subject><subject>Muscular Diseases - prevention & control</subject><issn>1933-2874</issn><issn>1876-4789</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp9UcuKFTEQDaI44-gPuJAs3fQ1r-4kIooMvmDEhYrLkE5Xz03bjzuptHL_3jR3nIULoSCnknMOlVOEPOVsxxlvXgy7wYdxJwresVLM3CPn3OimUtrY-wVbKSthtDojjxAHxupas_ohORO60UYJcU66z3721zDBnCnm5DNcR0AaZ3rwOZZbpL9j3pe30s6VR1xCLKyOTiuGESgep0NeJnxJf-x9phFp3gNtAe_8jm8ekwe9HxGe3J4X5Pv7d98uP1ZXXz58unx7VQXFea5UF_q2aTsbWm-t5ob1AFJILYJtCuDApJcKQu37wK0GwVXtm9Zyr1UrhLwgz0--h7TcrGUEN0UMMI5-hmVFx41QtaqtUYUqTtSQFsQEvTukOPl0dJy5LV03uC1dt6XrWClmiujZrf_aTtDdSf7GWQivTgQov_wVITkMJcQAXUwQsuuW-H__1__IwxjnGPz4E46Aw7KmueTnuEPhmPu67XdbL28kE2UI-Qf206HF</recordid><startdate>20160901</startdate><enddate>20160901</enddate><creator>Joy, Tisha R., MD, FRCPC, FACE</creator><creator>Brennan, Emily T., MD, FRCPC</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160901</creationdate><title>Management strategies in patients with statin-associated muscle symptoms: What is the best strategy?</title><author>Joy, Tisha R., MD, FRCPC, FACE ; Brennan, Emily T., MD, FRCPC</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-4dcfb6bd9cba997180fee32372c96e321e03a34ec5afc197e2145a6b91a74b223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Cardiovascular</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Substitution - methods</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</topic><topic>Lipid Metabolism - drug effects</topic><topic>Medication Therapy Management</topic><topic>Muscular Diseases - etiology</topic><topic>Muscular Diseases - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Joy, Tisha R., MD, FRCPC, FACE</creatorcontrib><creatorcontrib>Brennan, Emily T., MD, FRCPC</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical lipidology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Joy, Tisha R., MD, FRCPC, FACE</au><au>Brennan, Emily T., MD, FRCPC</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management strategies in patients with statin-associated muscle symptoms: What is the best strategy?</atitle><jtitle>Journal of clinical lipidology</jtitle><addtitle>J Clin Lipidol</addtitle><date>2016-09-01</date><risdate>2016</risdate><volume>10</volume><issue>5</issue><spage>1067</spage><epage>1072</epage><pages>1067-1072</pages><issn>1933-2874</issn><eissn>1876-4789</eissn><abstract>Highlights • Statin-associated muscle symptoms (SAMS) are commonly encountered. • Strategies are rechallenge, switch, nondaily statin dosing, or nonstatins. • Tolerability of each of these strategies is over 60%; efficacy is variable. • Several limitations are still encountered in the management of patients with SAMS. • Ultimately, patient involvement determines which strategy is most acceptable.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>27678422</pmid><doi>10.1016/j.jacl.2016.06.008</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1933-2874 |
ispartof | Journal of clinical lipidology, 2016-09, Vol.10 (5), p.1067-1072 |
issn | 1933-2874 1876-4789 |
language | eng |
recordid | cdi_proquest_miscellaneous_1824545984 |
source | ScienceDirect Freedom Collection 2022-2024 |
subjects | Cardiovascular Dose-Response Relationship, Drug Drug Substitution - methods Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Lipid Metabolism - drug effects Medication Therapy Management Muscular Diseases - etiology Muscular Diseases - prevention & control |
title | Management strategies in patients with statin-associated muscle symptoms: What is the best strategy? |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T02%3A54%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20strategies%20in%20patients%20with%20statin-associated%20muscle%20symptoms:%20What%20is%20the%20best%20strategy?&rft.jtitle=Journal%20of%20clinical%20lipidology&rft.au=Joy,%20Tisha%20R.,%20MD,%20FRCPC,%20FACE&rft.date=2016-09-01&rft.volume=10&rft.issue=5&rft.spage=1067&rft.epage=1072&rft.pages=1067-1072&rft.issn=1933-2874&rft.eissn=1876-4789&rft_id=info:doi/10.1016/j.jacl.2016.06.008&rft_dat=%3Cproquest_cross%3E1824545984%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c411t-4dcfb6bd9cba997180fee32372c96e321e03a34ec5afc197e2145a6b91a74b223%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1824545984&rft_id=info:pmid/27678422&rfr_iscdi=true |